水宽鱼大,CXO又回来了

药渡Daily
Yesterday

CXO的逻辑从来与创新药深度绑定:创新药是“水”,CXO是 “鱼”,当创新药投融资回暖、临床管线加速推进、商业化订单增多,CXO自然会“水涨船高”。过去两年,受全球创新药投融资收缩、药企控成本等因素影响,CXO行业经历了一轮估值调整;但2025年以来,随着创新药景气度的逐步回升,CXO行业也迎来了“水宽鱼大” 的新周期。近期披露的三季报数据显示,CXO企业业绩全面上扬,多家公司净利润创下历史新高,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10